Travere’s Kidney Disease Drug Narrowly Misses Phase III Endpoint, Stock Tanks
The company’s treatment for IgA nephropathy, sparsentan, failed to meet statistical significance by a measure of kidney function in a head-to-head confirmatory study versus irbesartan.